Antibiotic Resistance Market Research Report - Global Forecast till 2030

Antibiotic Resistance Market Research Report: Information By Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, Cephalosporins, and Combination Therapies), By Disease (Complicated Urinary Tract Infection, Blood Stream Infections, Complicated Intra-Abdominal Infections, Clostridium Difficile Infections, Acute Bacterial Skin, and Skin Structure Infections), By Pathogen (Staphylococcus Aureus, Streptococcus Pneumoniae, Acinetobacter, Enterococcus, and Hemophilus Influenzae), By End User (Hospitals & Clinics, and Research Organizatio

ID: MRFR/HC/7107-HCR | 90 Pages | Published By Rahul Gotadki on April 2023         

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Breakdown of Primary Respondents

3.5. Forecasting Techniques

3.6. Research Methodology for Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

5.3. Regulatory Framework

6. GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY DRUG CLASS

6.1. Overview

6.2. Oxazolidinones

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Lipoglycopeptides

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4. Tetracyclines

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5. Cephalosporins

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.6. Combination therapies

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.7. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7. GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY DISEASE

7.1. Overview

7.2. Complicated Urinary Tract Infection (cUTI)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Blood Stream Infections (BSI)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4. Complicated Intra-Abdominal Infections (cIAI)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5. Clostridium difficile infections (CDI)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.6. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.7. Hospital-Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.8. Community-Acquired Bacterial Pneumonia (CABP)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.9. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8. GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY PATHOGEN

8.1. Overview

8.2. Staphylococcus Aureus

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3. Streptococcus pneumoniae

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4. Acinetobacter

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.5. Enterococcus faecium

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.6. Hemophilus Influenzae

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.7. Pseudomonas aeruginosa

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.8. Clostridium difficile

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.9. K. pneumoniae

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.10. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9. GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY END USER

9.1. Overview

9.2. Hospitals & Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.3. Research Organizations

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.4. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

10. GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY REGION

10.1. Overview

10.2. Americas

10.2.1. North America

10.2.1.1. US

10.2.1.2. Canada

10.2.2. Latin America

10.3. Europe

10.3.1. Western Europe

10.3.1.1. Germany

10.3.1.2. France

10.3.1.3. Italy

10.3.1.4. Spain

10.3.1.5. UK

10.3.1.6. Rest of Western Europe

10.3.2. Eastern Europe

10.4. Asia-Pacific

10.4.1. Japan

10.4.2. China

10.4.3. India

10.4.4. Australia

10.4.5. South Korea

10.4.6. Rest of Asia-Pacific

10.5. Middle East & Africa

10.5.1. Middle East

10.5.2. Africa

11. COMPANY LANDSCAPE

11.1.1. Overview

11.1.2. Competitive Analysis

11.1.3. Market Share Analysis

11.1.4. Major Growth Strategy in the Global Antibiotic Resistance Market

11.1.5. Competitive Benchmarking

11.1.6. Leading Player in terms of Number of Developments in Global Antibiotic Resistance Market

11.1.7. Key Developments & Growth Strategies

11.1.7.1. Product Launch

11.1.7.2. Merger & Acquisition

11.1.7.3. Joint Ventures

11.1.8. Major Players Financial Matrix

11.1.8.1. Sales & Operating Income 2020

11.1.9. Major Players R&D Expenditure 2020

12. COMPANY PROFILES

12.1. Achaogen, Inc.

12.1.1. Company Overview

12.1.2. Product Overview

12.1.3. Financial Overview

12.1.4. Key Developments

12.1.5. SWOT Analysis

12.1.6. Key Strategies

12.2. Basilea Pharmaceutica Ltd.

12.3. MELINTA THERAPEUTICS, INC.

12.4. PARATEK therapeutics

12.5. Seres Therapeutics

12.6. Theravance Biopharma.

12.7. Entasis Therapeutics

12.8. Tetraphase Pharmaceuticals

12.9. Nabriva Therapeutics plc

12.10. NEMESIS BIOSCIENCE LTD

12.11. Procarta Biosystems

12.12. Allecra Therapeutics

12.13. Others

13. APPENDIX

13.1. References

13.2. Related Reports

NOTE:

This table of content is tentative and subject to change as the research progresses.

• In section 10, only top companies will be profiled. Each company will be profiled based on the Market Overview, Financials, Product Portfolio, Business Strategies, and Recent Developments parameters.

• Please note: The financial details of the company cannot be provided if the information is not available in the public domain and or from reliable sources.